03
2022-02
Suzhou, February 3, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the dosing of first subject in its U.S. phase I clinical trial of GT20029 (gel) for the treatment of androgenetic alopecia (AGA) and acne on 1 February 2022, US local time. Developed through Kintor’s proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the first topical PROTAC compound globally to enter the clinical stage.
24
2022-01
Suzhou, January 24, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("pyrilutamide") in China for the treatment of acne vulgaris.
02
2022-01
Suzhou, January 2, 2022 - Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first dosing in its phase III clinical trial of KX-826 in China for the treatment of male androgenetic alopecia (AGA) patients on December 31, 2021.
27
2021-12
Suzhou, December 27, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatment of COVID 19 infection (NCT04870606).
24
2021-11
Suzhou, November 24, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma, for the treatment of male androgenetic alopecia (“AGA”) patients was cleared by the National Medical Products Administration (“NMPA”). KX-826 is the first androgen receptor (AR) antagonist which has entered the phase III clinical trial for AGA treatment in China and global.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn